Oncology

A new partnership between Biocartis and City of Hope seeks to transform pancreatic cancer outcomes by pairing breakthrough biomarkers with rapid diagnostic technology.

With a novel 'gastric bypass in a pill' and a new CFO known for orchestrating lucrative exits, Syntis Bio is gearing up for a high-stakes battle in the booming obesity drug market.

Phase 2a data shows a new drug not only stops bone-destroying cancer but heals the damage, with no adverse events. This is a strategic game-changer.

A $20M round for CELYSTRA Pharma isn't just a launch; it's a strategic maneuver to solve Canada's rare disease gap and redefine Québec's role in the market.

As corporate giants swallow local clinics, one alliance offers a lifeline. Here’s how AllyGPO and BioCareSD use AI and service to help doctors stay independent.

Priority Health partners with Color Health, leveraging an ASCO-certified virtual clinic to tackle soaring cancer costs and redefine access for employers.

Blue Cross MA's new partnership with Thyme Care moves beyond paying for procedures, betting on a value-based model to guide patients and curb spiraling costs.

A patient with 'untreatable' colorectal cancer is disease-free for six years after a novel vaccine. But the real revolution may be the biopsy-free tech behind it.

A major study combining two powerful cancer drugs, KEYTRUDA and Trodelvy, has been halted, a setback for patients and a reality check for the industry.

Following its Ouro Medicines acquisition, Lakefront appoints veteran Eric Hedrick as CMO to drive its new immunology pipeline, signaling a bold transformation.

As Vivos Therapeutics pitches its revolutionary sleep apnea solution to investors, it's not just selling a device; it's fighting for its financial life.

A deadly, vaccine-less Ebola strain is spreading in Central Africa. As governments scramble, the CDC Foundation deploys its most potent weapon: agile funding.

New research from Baycrest unmasks paratonia, an involuntary condition often mistaken as defiance, signaling a seismic shift in dementia care and treatment.

As Capricor presents its late-stage DMD drug and novel exosome platform, can it convince investors it has the key to both patient impact and market success?

An aging world and failing antibiotics are driving a surge in pneumonia. Now, a new generation of therapies is being built to fight back. Here's how.

Eikon Therapeutics adds a consumer goods giant to its board, a move signaling a strategic pivot from pure science to global commercialization.

Johnson & Johnson's acquisition of Firefly Bio for $1 billion signals a major push into degrader antibody conjugates, a new frontier for treating KRAS cancers.

New research shows 'Food is Medicine' programs thrive when paired with human coaching, offering a potent, scalable model for tackling chronic disease.

As GLP-1 drugs dominate, a UK biotech reveals a new drug that targets mitochondria, promising superior fat loss while preserving precious muscle mass.

Kymera Therapeutics' new lupus data isn't just about a drug. It's about a new strategy: erasing disease-causing proteins to build resilient value.